Physician profile
Krysten Raymond
NPI 1255571451
$6,627.19
in general payments reported to CMS, 2019-2025
32 companies · $1,689 in 2025
The $1,689 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.32 · 2022: $980 · 2023: $1,759 · 2024: $2,172 · 2025: $1,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,554 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,553.89 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,091.03 | 2021-2025 | |
| Novo Nordisk INC | $619.95 | 2023-2025 | Wegovy |
| Lilly USA, LLC | $509.60 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $414.54 | 2022-2025 | Verquvo, Gardasil 9, Capvaxive |
| Amgen INC. | $390.90 | 2022-2025 | Repatha, Otezla, Prolia |
| Novartis Pharmaceuticals Corporation | $355.83 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $345.53 | 2022-2025 | Quviviq, Quviviq |
| Astellas Pharma US INC | $336.20 | 2022-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $331.05 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $278.05 | 2023-2025 | |
| Scilex Pharmaceuticals INC. | $273.06 | 2024-2025 | |
| Exact Sciences Corporation | $272.84 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.73 | 2022-2025 | Jardiance, Synjardy, Ofev |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $218.71 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $195.76 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $129.50 | 2024-2025 | Auvelity |
| Alnylam Pharmaceuticals INC. | $122.83 | 2023 | Amvuttra |
| Renalytix Ai, INC. | $65.27 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Esperion Therapeutics, INC. | $62.86 | 2022-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $46.90 | 2023 | Trintellix |
| Abbott Laboratories | $45.67 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $44.92 | 2024-2025 | Voquezna |
| Impel Pharmaceuticals INC. | $40.72 | 2023 | Trudhesa |
| Corcept Therapeutics | $33.99 | 2023 | Korlym |
| Janssen Pharmaceuticals, INC | $32.63 | 2025 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $25.87 | 2022 | |
| Amneal Pharmaceuticals LLC | $23.37 | 2024 | Unithroid |
| Sumitomo Pharma America, INC. | $21.56 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $20.96 | 2022 | |
| Dexcom, INC. | $19.97 | 2023 | Dexcom G6 Transmitter |
| Vivus LLC | $18.72 | 2024 | Qsymia |
| Almatica Pharma LLC | $18.67 | 2023 | Loreev Xr, Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krysten Raymond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.